[Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
OBJECTIVE
Cancer cell growth is supported by glucose metabolism of glucose transporter protein 1 (GLUT-1). In addition, the participation of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in genome damage-repairing is important for oncogenesis prevention. This study was to evaluate the expression and biologic significance of GLUT-1 and DNA-PKcs in serous ovarian tumors.


METHODS
The expression of GLUT-1 and DNA-PKcs in 20 specimens of normal ovarian tissues, 20 specimens of serous cystadenoma, 20 specimens of borderline serous cystadenoma, and 40 specimens of serous cystadenocarcinoma were detected by SP immunohistochemistry. The correlation of GLUT-1 and DNA-Pkcs expression to clinicopathologic characteristics of serous ovarian tumors was analyzed by Chi-square test.


RESULTS
The positive rate of GLUT-1 was significantly higher in malignant and borderline serous ovarian carcinomas than in benign tumors and normal ovarian tissues (100% and 55% vs. 0% and 0%, P<0.01). The differences in the positive rate of DNA-PKcs were significant among normal ovarian tissues, benign, borderline, and malignant serous ovarian tumors (100%, 95%, 90%, and 60%, P<0.01). GLUT-1 expression was negatively correlated to DNA-PKcs expression (rs = -0.270, P<0.01). GLUT-1 expression in borderline and malignant serous ovarian tumors was related to intraperitoneal implants, ascites, lymph node metastasis, and FIGO stage, but DNA-PKcs was only related to FIGO stage and lymph node metastasis (P<0.05).


CONCLUSIONS
The expression of GLUT-1 and the loss of DNA-PKcs may be closely related to the malignant transformation of serous ovarian tumors.
Cai
Yu
Y
Department of Gynecology and Obstetrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, PR China. caiyu892002@sina.com
Shao
Shu-Li
SL
Wang
Quan-Hong
QH
Yan
Li-Juan
LJ
Wang
Xiao-Yan
XY
Wang
Li-Xia
LX
D000293:Adolescent; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D018293:Cystadenoma, Serous / Q000378:metabolism* / Q000473:pathology; D051747:DNA-Activated Protein Kinase / Q000378:metabolism*; D005260:Female; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D055815:Young Adult
D051272:Glucose Transporter Type 1; D009687:Nuclear Proteins; D051747:DNA-Activated Protein Kinase; C497263:PRKDC protein, human